<DOC>
	<DOCNO>NCT02151786</DOCNO>
	<brief_summary>The purpose survey evaluate safety ( i.e. , frequency adverse event ) efficacy ( i.e. , hemostatic effect , rate rebleeding confirmation hemostasis ) administration lansoprazole intravenous 30 milligram ( mg ) ( Takepron Intravenous 30 mg ) large number patient daily medical practice .</brief_summary>
	<brief_title>Lansoprazole Intravenous 30 mg Specified Drug-use Survey Hemostatic Effect/Rebleeding Rate</brief_title>
	<detailed_description>This survey design evaluate safety ( i.e. , frequency adverse event ) efficacy ( i.e. , hemostatic effect , rate rebleeding confirmation hemostasis ) administration lansoprazole intravenous 30 mg ( Takepron Intravenous 30 mg ) large number participant daily medical practice . For adult , 30 mg lansoprazole typically mixed physiological saline ( JP ) 5 % glucose solution injection ( JP ) administer twice daily drip infusion dissolve 20 mL physiological saline ( JP ) 5 % glucose solution injection ( JP ) administer twice daily direct slow intravenous injection .</detailed_description>
	<mesh_term>Duodenal Ulcer</mesh_term>
	<mesh_term>Gastritis</mesh_term>
	<mesh_term>Stomach Ulcer</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Hemostatics</mesh_term>
	<criteria>Patients follow disease oral administration feasible : Gastric ulcer , duodenal ulcer , acute stress gastritis , acute gastric mucosal lesion ( accompanied bleeding ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Pharmacological therapy</keyword>
</DOC>